Stock Events

Stock Events

Cara Therapeutics 

€0
65
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-7.08
-4.91
-2.74
-0.57
Expected EPS
-0.595
Actual EPS
N/A

Financials

-1,122.07%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
5.2MRevenue
-58.32MNet Income

Analyst Ratings

$5.56Average Price Target
The highest estimate is 11.38.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
25%
Hold
75%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 69C0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in creating treatments for pain management, directly competing with Cara Therapeutics' focus on novel pain therapies.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries has a broad portfolio that includes pain management solutions, making it a competitor in the same therapeutic area as Cara Therapeutics.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment, develops drugs for various conditions including pain, competing with Cara Therapeutics' pain management products.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a strong presence in the pain management market with its portfolio of analgesics, competing with Cara Therapeutics.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diverse drug portfolio that includes pain management medications, positioning it as a competitor to Cara Therapeutics.
Novartis
NVS
Mkt Cap237.61B
Novartis AG offers a range of pain management solutions, making it a direct competitor in the therapeutic area that Cara Therapeutics targets.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. develops medications for various therapeutic areas, including pain, competing with Cara Therapeutics' focus.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, though primarily known for antiviral drugs, has ventured into other therapeutic areas, including pain management, competing with Cara Therapeutics.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes plc works on central nervous system (CNS) disorders, including treatments for pain, positioning it as a competitor to Cara Therapeutics.

About

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Show more...
CEO
Dr. Imran Alibhai Ph.D.
Employees
17
Country
US
ISIN
US1407552082
WKN
000A40WYX

Listings

XNAS
US
TVRD
LSE
GB
0HTC.LSE
F
DE
69C.F
BOATS
BOATS
TVRD.BOATS

0 Comments

Share your thoughts

FAQ

What is Cara Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cara Therapeutics stocks are traded under the ticker 69C0.F.
What is Cara Therapeutics revenue for the last year?▼
Cara Therapeutics revenue for the last year amounts to 5.2M EUR.
What is Cara Therapeutics net income for the last year?▼
69C0.F net income for the last year is -58.32M EUR.
How many employees does Cara Therapeutics have?▼
As of April 03, 2026, the company has 17 employees.
In which sector is Cara Therapeutics located?▼
Cara Therapeutics operates in the Health Care sector.
When did Cara Therapeutics complete a stock split?▼
The last stock split for Cara Therapeutics was on December 31, 2024 with a ratio of 1:12.
Where is Cara Therapeutics headquartered?▼
Cara Therapeutics is headquartered in Sugar Land, US.